Compare SIDU & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIDU | MOLN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 158.9M |
| IPO Year | 2021 | 2021 |
| Metric | SIDU | MOLN |
|---|---|---|
| Price | $2.69 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 5.8M | 3.6K |
| Earning Date | 05-14-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,672,646.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | $318.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $3.36 |
| 52 Week High | $5.39 | $5.36 |
| Indicator | SIDU | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 40.25 |
| Support Level | $0.89 | $4.04 |
| Resistance Level | $4.40 | $4.63 |
| Average True Range (ATR) | 0.28 | 0.27 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 65.76 | 16.45 |
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.